The sale is small and part of a pre-arranged 10b5-1 plan, so it does not signal a change in insider sentiment. Monitor for any acceleration of insider selling or changes to the 10b5-1 plan.
CTNM drugs
CTNM drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $8.81entry
- T+1 · 11d ago +8.06%α +7.75% · $9.52
- T+5 · 5d ago +11.01%α +7.72% · $9.78
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Daniel S. Lorrain, an officer of Contineum Therapeutics, filed a Form 144 notice of intent to sell 4,170 shares of common stock, valued at approximately $40,407 based on a recent market price of ~$9.69. The shares were acquired via restricted stock units in 2017. This is a relatively small sale relative to the company's $360M market cap and the insider's apparent holdings, and is part of a 10b5-1 plan with prior sales in September and October 2026.
Key Facts
- Daniel S. Lorrain, an officer of Contineum Therapeutics, filed Form 144 on 2026-11-04.
- Proposed sale of 4,170 shares of common stock, approximate value $40,407.
- Shares acquired on 05/09/2017 via restricted stock units.
- Sale is part of a 10b5-1 trading plan; prior sales occurred on 09/01/2026 (9,520 shares) and 10/01/2026 (4,170 shares).
- Company market cap is $360M; the proposed sale represents ~0.01% of shares outstanding.
Financial Impact
Proposed sale of 4,170 shares worth ~$40,407, a small fraction of the officer's likely holdings and the company's market cap.
Risk Factors
- Insider selling, even under a 10b5-1 plan, can be perceived negatively by the market if it continues at an elevated pace.
- No other insider transactions or company filings are provided for context; this is an isolated filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-010677 |
| Document: 0001950047-26-010677-index.html | 0001950047-26-010677 |
| Document: 0001950047-26-010677.txt | 0001950047-26-010677 |
Track record
14 reports on CTNM
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $9.72 Now $9.67 −0.46% settles Dec 15
- Nov 10, 20266d ago Institutional Cluster Neutral 2/10 Entry $10.56 Now $9.67 −8.43% settles Dec 9
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $9.52 Now $9.67 +1.58% settles Dec 7
- Nov 5, 202611d ago SC 13G Neutral 4/10 Entry $8.81 Now $9.67 +9.76% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Viewing Entry $8.81 Now $9.67 +9.76% settles Dec 4
- Nov 3, 202613d ago 8-K Neutral 3/10 Entry $9.79 Now $9.67 −1.23% settles Dec 3
- Oct 28, 202619d ago SC 13G Neutral 3/10 Entry $9.33 Now $9.67 +3.64% settles Nov 27
- Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $9.15 Now $9.67 +5.68% settles Nov 25
- Oct 22, 202625d ago SC 13G Neutral 3/10 Entry $8.31 Now $9.67 +16.37% settles Nov 20
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $13.40 to $8.46 Now $9.67 −27.84% ▼ −36.87% −36.31% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers